Archive for the ‘News’ Category

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s disease clinical trial

Wednesday, July 25th, 2018

Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the  RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been […]

Crohn’s disease clinical trial – Now enrolling

Monday, July 9th, 2018

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]

Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board

Wednesday, May 16th, 2018

Vancouver, British Columbia – May 15th, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the addition of four members to Qu’s Scientific Advisory Board (SAB), consisting of world leading experts in the fields of innate […]

Qu Biologics SSIs featured in Inside Tract magazine

Thursday, May 10th, 2018

Qu Biologics’ paradigm shifting approach to IBD is featured in the March April 2018 issue of the Gastrointestinal Society’s ‘Inside Tract’ magazine. Read the full article here

Qu Biologics begins Phase 2 Clinical Trial in Crohn’s disease

Friday, April 20th, 2018

Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore innate immune function, is pleased to announce the receipt of a ‘No Objection Letter’ (NOL) from Health Canada and the initiation of their follow-on Phase 2 clinical trial to study QBECO SSI for […]

Julia Levy – a trailblazer for women in STEM

Wednesday, April 4th, 2018

A woman of wisdom and influence and we’re proud to be associated – Julia Levy is a member of Qu Biologics Board of Directors and has blazed a trail for women in STEM. Read more about her journey here .  

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Wednesday, December 20th, 2017

Vancouver, British Columbia – Dec 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system is pleased to report that they will be presenting clinical outcome data from Qu’s recently completed Phase 2 study in ulcerative colitis at […]

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Tuesday, November 28th, 2017

Vancouver, British Columbia – November 28th, 2017 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the […]

Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers

Tuesday, October 3rd, 2017

Vancouver, British Columbia – October 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has identified specific ulcerative colitis (UC) genetic markers that may predict response to QBECO SSI therapy and important immunological biomarkers that may be […]

Positive feedback from FDA reviewers in response to Pre-IND meeting package

Monday, August 14th, 2017

Vancouver, British Columbia – August 14th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports positive and informative feedback from the US Food and Drug Administration (FDA) in response to Qu’s first Pre-IND meeting package submission. The […]

Past events:


Past events: